All posts

Is Canopy Growth a buy in this market? (April, 2023)

What does Canopy Growth do?

Canopy Growth is a Canadian cannabis company that produces and sells a wide range of cannabis products, including dried flowers, oils, capsules, and vape cartridges. The company also has a portfolio of brands, including Tweed, Spectrum Therapeutics, and Tokyo Smoke. Canopy Growth operates across multiple countries, including Canada, the United States, Germany, and the United Kingdom, and is focused on expanding its global presence in the legal cannabis industry. The company is also involved in research and development of new cannabis-based products, as well as partnerships with other companies in the industry.

What is Canopy Growth’s ticker symbol?

Canopy Growth’s stock trades on the Toronto Stock Exchange (TSX) and the NASDAQ. On the TSX, the ticker symbol is “WEED”, and on the NASDAQ, it is “CGC”.

Where is Canopy Growth based?

Canopy Growth is based in Smiths Falls, Ontario, Canada.

Who are the major shareholders of Canopy Growth?

As of its latest available public filings, the top institutional shareholders of Canopy Growth Corporation are The Vanguard Group, Inc., Constellation Brands, Inc., and BlackRock, Inc. The top individual shareholders are its former CEO Bruce Linton, and its current CEO David Klein.

Does Canopy Growth have strong margins?

Canopy Growth Corporation is a Canadian cannabis company that operates in a highly regulated industry with significant costs and constraints. As of the latest financial statements available (Q3 2022), Canopy Growth reported a gross margin of 10%, which is relatively low compared to other industries but is common for companies in the cannabis industry. The company’s net loss margin for the same period was -69%, indicating that the company is not currently profitable. It’s worth noting that the cannabis industry is still in the early stages of development, and many companies are still investing heavily in research and development, production capacity, and marketing to capture market share, which may impact their profitability in the short term.

Who are Canopy Growth’s competitors?

Canopy Growth’s competitors include other major cannabis producers such as Aurora Cannabis, Tilray, Cronos Group, and Aphria.

Do analysts like Canopy Growth stock?

It’s difficult to provide a definitive answer on whether analysts like Canopy Growth stock, as opinions can vary among different analysts and can change over time. However, here are some recent analyst ratings and price targets for Canopy Growth:

  • According to MarketBeat, as of April 16, 2023, the consensus rating among 17 Wall Street analysts covering Canopy Growth is a “hold,” with an average price target of $19.90.
  • Among the 15 analysts tracked by CNN Business, as of April 16, 2023, the consensus rating for Canopy Growth is a “hold,” with an average price target of $20.87.

It’s worth noting that analyst opinions can be influenced by a variety of factors, including market conditions, company performance, and industry trends. Investors should always conduct their own research and consider multiple sources of information before making investment decisions.

Here are some analysts who cover Canopy Growth and their price targets as of my knowledge cutoff date (September 2021):

  • BMO Capital Markets: Price target of CAD 34
  • Cowen and Company: Price target of USD 30
  • Jefferies Financial Group: Price target of USD 38
  • Piper Sandler: Price target of USD 35
  • RBC Capital Markets: Price target of CAD 42
  • Stifel Nicolaus: Price target of USD 33

Please keep in mind that these price targets may have changed since then and that this is not an exhaustive list of all analysts covering Canopy Growth.

Disclaimer

The information provided in this article is for educational and informational purposes only and should not be construed as investment advice. The content of this article is not intended to provide investment, financial, or legal advice and should not be relied upon as such. The author and the publisher of this article are not registered investment advisors or broker-dealers and do not purport to provide personalized investment advice. Any investment decisions that you make based on the information contained in this article are at your own risk. It is recommended that you consult with a qualified investment advisor, accountant, and/or attorney before making any investment decisions. The author and the publisher of this article are not responsible for any investment losses that you may incur as a result of using the information contained in this article.

 

 

 

 

 

 

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: weed
ChatGPT

ChatGPT is a large language model developed by OpenAI, based on the GPT-3.5 architecture. It was trained on a massive amount of text data, allowing it to generate human-like responses to a wide variety of prompts and questions. ChatGPT can understand and respond to natural language, making it a valuable tool for tasks such as language translation, content creation, and customer service. While ChatGPT is not a sentient being and does not possess consciousness, its sophisticated algorithms allow it to generate text that is often indistinguishable from that of a human.

Recent Posts

Is GOOGL still a buy?

Following a widely applauded first quarter beat, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Alphabet (Alphabet… [Read More]

16 hours ago

NLH has 173% upside, Echelon says

Following an acquisition, Echelon Capital Markets analyst Stefan Quenneville has maintained his "Buy" rating on Nova Leap Health (Nova Leap… [Read More]

16 hours ago

Shopify upgraded to “Buy” at Citi

The stock has been flat since November, but Citi analyst Tyler Radke thinks there is now money to be made… [Read More]

17 hours ago

Sabio has 400% upside, Eight Capital says

Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]

3 days ago

Is SNAP a buy right now?

He feels the company made forward progress in its recent quarterly results, but Roth MKM analyst Rohit Kulkarni wants to… [Read More]

3 days ago

Bombardier wins price target raise at Desjardins

Following the company's first quarter results, Desjardins analyst Benoit Poirier has raised his price target on Bombardier (Bombardier Stock Quote,… [Read More]

4 days ago